Registration, quality assurance and the shape of a medicines contract
A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programs -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.
Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.
The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and program funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.
This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.
Who buys pharmaceuticals in Finland?
GlobalGov holds 434 pharmaceuticals records from 99 distinct buying organizations in Finland. The most frequent publishers are EU Agency (18 records); Ministry of Social Affairs and Health (16 records); Sansia Oy (12 records); Helsingin kaupungin sosiaali- ja terveystoimiala (10 records); HUS-yhtymä (8 records); Helsingin kaupungin sosiaali-, terveys- ja pelastustoimiala (8 records). Between them the 6 largest account for 17% of everything published, so buying here is spread across many separate authorities.
| Buying organization | Records | Share |
|---|---|---|
| EU Agency | 18 | 4.1% |
| Ministry of Social Affairs and Health | 16 | 3.7% |
| Sansia Oy | 12 | 2.8% |
| Helsingin kaupungin sosiaali- ja terveystoimiala | 10 | 2.3% |
| HUS-yhtymä | 8 | 1.8% |
| Helsingin kaupungin sosiaali-, terveys- ja pelastustoimiala | 8 | 1.8% |
What are pharmaceuticals contracts worth in Finland?
150 of the 434 records publish a contract value. The median is $4.7M and the largest single published value is $587.6M. By size, 1 under $100k, 42 between $100k and $1M, 65 between $1M and $10M, 42 above $10M. The remaining 284 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.
| Contract size | Records | Share of priced |
|---|---|---|
| under $100k | 1 | 0.7% |
| between $100k and $1M | 42 | 28% |
| between $1M and $10M | 65 | 43% |
| above $10M | 42 | 28% |
How long do bidders get to respond to pharmaceuticals tenders in Finland?
Across the 75 Finland pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 34 days. A quarter of them allowed 34 days or fewer and a quarter stayed open for more than 85. Short turnarounds are the exception rather than the rule here: only 6 (8.0%) closed within a fortnight of being published.
How often are pharmaceuticals tenders published in Finland?
Finland publishes about 8 notices a month in this category, 98 in the last twelve months. That is 238% more than the 29 published in the twelve months before that. Over the last three years there were 174, spread across 89 separate months of activity since 17 February 2011. May is historically the busiest month. The most recent was published 16 November 2026.
How does Finland compare with other pharmaceuticals markets?
Among the 45 countries where GlobalGov holds a comparable pharmaceuticals market, Finland ranks 21st by number of records. The largest is Poland (9,417 records against 434 here). Within Finland itself, pharmaceuticals is the 22nd largest of the 51 procurement categories tracked here.
Where do the Finland pharmaceuticals records on this page come from?
These 434 records are collected from 2 official sources: TED (325), Hilma (109). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-11-22.
Open Pharmaceuticals tenders in Finland
Showing 3 of the 9 notices open in this category today. Openness uses the same definition as the Finland market page: active, not marked awarded, cancelled, closed or expired, and either closing in the future or published within the last 90 days with no stated closing date.
Finland – Pharmaceutical products – Medicinal Products and Equivalent Preparations DPS
Finland – Pharmaceutical products – Request For Information – Supply of Boronophenylalanine for pharmaceutical preparation of compound for BNCT treatment
Other procurement categories in Finland
Pharmaceuticals procurement in other markets
Never Miss a Finland Government Contract
Finding Finland tenders usually means a local portal, a local registration and someone who reads the language. Get an alert you can read when a new pharmaceuticals opportunity is published there.
Start Free Trial